A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

Exclusion Criteria

• •Part A and B:
• •1. Significant health issues, such as positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), active tuberculosis, immunodeficiencies or autoimmune diseases.
• •2. History of major metabolic, liver, kidney, hematologic or other significant disorders.
• •3. Abnormal Electrocardiogram (ECG) findings
• •4. Clinically relevant abnormal lab results, including low blood counts, or abnormal liver and kidney function.
• •5. History of drug abuse or addiction within 6 months prior to screening
• •6. Current smoker or use of any nicotine or tobacco containing products within the last 6 months prior to dosing.
• •7. Donated \>500mL blood within 2 months of dosing.
• •For Part B only:
• •1. Presence of dermatologic conditions and/or comorbidities that might confound the diagnosis of AD and/or might interfere with study assessments.
• •2. Uncontrolled chronic disease that might require bursts of oral corticosteroids.
• •3. Any other sound medical, psychiatric, and/or social reason as determined by the investigator.